Intravitreal triamcinolone acetonide in sympathetic ophthalmia.
OBJECTIVE
To report the result of intravitreal triamcinolone acetonide in the treatment of sympathetic ophthalmia.


METHODS
A 29-year-old woman who suffered from sympathetic ophthalmia and who was being treated with systemic corticosteroid therapy received an intravitreal injection of 4 mg of triamcinolone acetonide.


RESULTS
By the 15th day after injection visual acuity had improved from 20/200 to 20/40 and serous retinal detachment had almost completely resorbed. Systemic corticosteroid therapy was reduced sequentially. By the third month after injection, the patient was in clinical remission. Her visual acuity was 20/20 and no serous detachment was observed.


CONCLUSIONS
In this study, short-term improvement in the clinical picture of a patient with sympathetic ophthalmia after intravitreal triamcinolone acetonide injection was described. The results suggest that intravitreal triamcinolone acetonide injection may be an additional tool in the treatment of sympathetic ophthalmia.
Ozdemir
Hakan
H
Istanbul Retina Institute Inc., Hakki Yeten Cad., No: 8/7, Sisli 34349 Istanbul, Turkey.
Karacorlu
Murat
M
Karacorlu
Serra
S
D000208:Acute Disease; D000328:Adult; D005260:Female; D005451:Fluorescein Angiography; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007267:Injections; D009879:Ophthalmia, Sympathetic / Q000188:drug therapy*; D041623:Tomography, Optical Coherence; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*; D014792:Visual Acuity; D014822:Vitreous Body
D005938:Glucocorticoids; D014222:Triamcinolone Acetonide